Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Over the past few decades, the gonadotropin-releasing hormone agonist goserelin has been evaluated in ovarian function suppression (OFS) with adjuvant endocrine therapy and ovarian function preservation (OFP) during chemotherapy.
Objective: The goal of this systematic literature review was to assess the efficacy of goserelin in OFS and OFP in combination with endocrine therapies and chemotherapy, respectively, in pre- and perimenopausal women with early-stage breast cancer.
Design: This study is a systematic review.
Data Sources And Methods: The literature search was conducted using PubMed. Prospective clinical studies evaluating the efficacy of goserelin in OFS or OFP in pre- or perimenopausal breast cancer were identified by four reviewers working in teams of two.
Results: Twenty-nine studies were included in this systematic review. The addition of goserelin as OFS to adjuvant endocrine therapy generally resulted in significant benefits in disease-free survival. Studies have shown better OFP results among women 40 years or younger compared with older patients. Chemotherapy in association with goserelin for OFP resulted in a higher recovery rate of menses within 6-24 months, a shorter time for menstrual recovery, and significantly higher pregnancy rates when compared with cytotoxic therapy without goserelin. Hormonal recovery with higher anti-Müllerian hormone and estradiol levels, and lower follicle-stimulating hormone and luteinizing hormone levels occurred more frequently among women who received goserelin during chemotherapy as compared with those receiving cytotoxic therapy alone. The benefits of goserelin in OFP were more substantial among women 40 years or younger than in older patients.
Conclusion: The findings of this systematic review highlight the benefits of adding goserelin to endocrine therapies for OFS and chemotherapy for OFP in early-stage breast cancer. Additionally, scientific data supporting OFS (including goserelin) in combination with newer agents such as cyclin-dependent kinase 4 and 6 inhibitors and bone-modifying agents are emerging.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837078 | PMC |
| http://dx.doi.org/10.1177/17588359251319696 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.
J Clin Oncol
August 2025
US Food and Drug Administration, Silver Spring, MD.
Purpose: On September 17, 2024, the US Food and Drug Administration (FDA) approved ribociclib in combination with an aromatase inhibitor (AI) for the adjuvant treatment of adults with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer (EBC) who are at high risk of recurrence.
Patients And Methods: The FDA approval was based on NATALEE, a randomized (1:1), open-label, multicenter, multinational trial in adults of any sex or menopausal status with hormone receptor-positive, HER2-negative stage II and III EBC who received ribociclib plus an AI (Ribo + AI, n = 2,549) versus an AI (n = 2,552); patients also received goserelin as clinically indicated. Ribociclib was given at 400 mg once daily (3 weeks on/1 week off) for up to 36 months.
Rocket-Like Microneedle Patch for Sustained Hormone Therapy in Prostate Cancer.
ACS Biomater Sci Eng
August 2025
Department of Biomedical Engineering, National Cheng Kung University, Tainan 70101, Taiwan.
Prostate cancer (PCa) remains a significant global health challenge, necessitating the development of advanced therapeutic strategies. This study introduces a rocket-like microneedle patch (RLMNP) as a dual-layer drug delivery system for sustained hormone therapy in PCa. RLMNP integrates a rapid-release layer, employing the pH-responsive zeolitic imidazolate framework-8 (ZIF-8) to encapsulate bicalutamide (CDX), and a sustained-release layer comprising an alginate-tyramine (Alg-Tyr) hydrogel loaded with goserelin.
View Article and Find Full Text PDFCase Report: Surgical androgen deprivation therapy for prostate cancer in a patient with concurrent scrotal paget's disease.
Front Oncol
June 2025
The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Department of Urology II, Kunming, China.
Introduction: Prostate cancer (PCa) and Scrotal Paget's disease (SPD) are two distinct malignancies, and reports of their concurrent occurrence are very limited. The aim of this case was to discuss the individualized treatment strategy for an elderly patient with metastatic PCa combined with SPD.
Case Presentation: An octogenarian male (aged 88 years) with metastatic PCa (Gleason 8 = 4 + 4, bone metastases, suspected lung involvement) received androgen deprivation therapy (ADT: bicalutamide + goserelin), achieving biochemical control (PSA <0.
LH-RH agonist monotherapy for androgen receptor-positive recurrent and/or metastatic salivary gland cancer: a retrospective study.
Int J Clin Oncol
August 2025
Department of Head and Neck Medical Oncology, National Cancer Center East Hospital, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-0881, Japan.
Background: Although combination therapy consisting of a luteinizing hormone-releasing hormone (LH-RH) agonist and an Androgen receptor (AR) inhibitor has demonstrated promising clinical activity for recurrent and/or metastatic SGC (R/M SGC), few studies on LH-RH agonist monotherapy have been reported.
Methods: We conducted a retrospective analysis of patients with AR-positive, R/M SGC treated by monotherapy with LH-RH agonists in our institution from November 2004 to July 2023.
Results: Nineteen patients were identified; the median age was 64 years (range 42-82), 10 had salivary duct carcinoma (52.
A Non-Inferior Randomized Trial of Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Premenopausal Patients With Hormone-Responsive and HER2-Negative Lymph Node-Negative Breast Cancer.
Cancer Control
May 2025
Breast Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
ObjectivesNeoadjuvant endocrine therapy (NET) has demonstrated efficacy in postmenopausal patients with hormone-responsive and HER2-negative breast cancer. However, few data are available on NET in premenopausal women. This trial was designed to compare the effectiveness of neoadjuvant chemotherapy (NCT) with NET in premenopausal patients with hormone-responsive, HER2-negative, and lymph node-negative breast cancer.
View Article and Find Full Text PDF